Current Neuro-Oncology

Volume 16 Number 3
31 March 2014

Home > Publications > Current Neuro-Oncology > Volume 16, Year 2014 > Number 3, 31 March

ˍ

Kool M, Jones DT, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro RM, Esparza LA, Markant SL, Remke M, Milde T, Bourdeaut F, Ryzhova M, Sturm D, Pfaff E, Stark S, Hutter S, Seker-Cin H, Johann P, Bender S, Schmidt C, Rausch T, Shih D, Reimand J, Sieber L, Wittmann A, Linke L, Witt H, Weber UD, Zapatka M, König R, Beroukhim R, Bergthold G, van Sluis P, Volckmann R, Koster J, Versteeg R, Schmidt S, Wolf S, Lawerenz C, Bartholomae CC, von Kalle C, Unterberg A, Herold-Mende C, Hofer S, Kulozik AE, von Deimling A, Scheurlen W, Felsberg J, Reifenberger G, Hasselblatt M, Crawford JR, Grant GA, Jabado N, Perry A, Cowdrey C, Croul S, Zadeh G, Korbel JO, Doz F, Delattre O, Bader GD, McCabe MG, Collins VP, Kieran MW, Cho YJ, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya RJ, Lichter P, Pfister SM; ICGC PedBrain Tumor Project.
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.
Cancer Cell. 2014 Mar 17;25(3):393-405∟. doi: 10.1016/j.ccr.2014.02.004∟. PMID: 24651015∟. Laboratory investigation. ˍ

Malkki H.
Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
Nat Rev Neurol. 2014 Mar 18, 2014;10(4):179∟. doi: 10.1038/nrneurol.2014.47∟. PMID: 24638136∟. Comment. ˍ
Refers to: Chinot OL, et al., Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):709-22∟. doi: 10.1056/NEJMoa1308345∟. PMID: 24552318∟. Interventional study. ˍ
Refers also to: Gilbert MR, et al., A randomized trial of bevacizumab for newly diagnosed glioblastoma.
N Engl J Med. 2014 Feb 20;370(8):699-708∟. doi: 10.1056/NEJMoa1308573∟. PMID: 24552317∟. Interventional study. ˍ